Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, Messina JL, Smalley KSM.

Semin Cancer Biol. 2019 Nov 2. pii: S1044-579X(19)30343-8. doi: 10.1016/j.semcancer.2019.10.017. [Epub ahead of print] Review.

PMID:
31689494
2.

A Roadmap for the Computational Prediction and Experimental Validation of Competitive Endogenous RNAs.

Karreth FA.

Methods Mol Biol. 2019;1970:237-250. doi: 10.1007/978-1-4939-9207-2_13.

PMID:
30963496
3.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
4.

An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.

Vera O, Rodriguez-Antolin C, de Castro J, Karreth FA, Sellers TA, Ibanez de Caceres I.

Epigenetics. 2018;13(3):251-263. doi: 10.1080/15592294.2018.1436364. Epub 2018 Apr 2.

5.

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.

Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4. Erratum in: Cancer Discov. 2018 Aug;8(8):1044.

6.

Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth FA, Trevino JG, Merchant N, Magliocco A, Malafa MP, Gillies R.

Sci Rep. 2017 Sep 5;7(1):10484. doi: 10.1038/s41598-017-09754-5.

7.

Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.

Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J.

Mol Cell. 2017 Aug 3;67(3):512-527.e4. doi: 10.1016/j.molcel.2017.06.033. Epub 2017 Jul 27.

8.

The utility of transposon mutagenesis for cancer studies in the era of genome editing.

DeNicola GM, Karreth FA, Adams DJ, Wong CC.

Genome Biol. 2015 Oct 19;16:229. doi: 10.1186/s13059-015-0794-y. Review.

9.

The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.

Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Velasco-Herrera Mdel C, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP.

Cell. 2015 Apr 9;161(2):319-32. doi: 10.1016/j.cell.2015.02.043. Epub 2015 Apr 2.

10.

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45. doi: 10.1073/pnas.1418163112. Epub 2015 Jan 26.

11.

Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.

Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP.

Cell Rep. 2014 Aug 7;8(3):714-22. doi: 10.1016/j.celrep.2014.06.064. Epub 2014 Jul 31.

12.

Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.

Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C.

J Natl Cancer Inst. 2014 Jul 25;106(8). pii: dju182. doi: 10.1093/jnci/dju182. Print 2014 Aug.

13.

Target competition: transcription factors enter the limelight.

Karreth FA, Tay Y, Pandolfi PP.

Genome Biol. 2014 Apr 28;15(4):114. doi: 10.1186/gb4174.

14.

Pseudogenes as competitive endogenous RNAs: target prediction and validation.

Karreth FA, Ala U, Provero P, Pandolfi PP.

Methods Mol Biol. 2014;1167:199-212. doi: 10.1007/978-1-4939-0835-6_13.

PMID:
24823779
15.

Aberrant ceRNA activity drives lung cancer.

Tay Y, Karreth FA, Pandolfi PP.

Cell Res. 2014 Mar;24(3):259-60. doi: 10.1038/cr.2014.21. Epub 2014 Feb 14. No abstract available.

16.

ceRNA cross-talk in cancer: when ce-bling rivalries go awry.

Karreth FA, Pandolfi PP.

Cancer Discov. 2013 Oct;3(10):1113-21. doi: 10.1158/2159-8290.CD-13-0202. Epub 2013 Sep 26. Review.

17.

Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments.

Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Léopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7154-9. doi: 10.1073/pnas.1222509110. Epub 2013 Mar 27.

18.

Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA.

Gut. 2012 Jun;61(6):877-84. doi: 10.1136/gutjnl-2011-300850. Epub 2011 Dec 9.

PMID:
22157328
19.

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA.

Cancer Discov. 2011 Jul;1(2):128-36. doi: 10.1158/2159-8290.CD-10-0044. Epub 2011 May 11.

20.

In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP.

Cell. 2011 Oct 14;147(2):382-95. doi: 10.1016/j.cell.2011.09.032. Erratum in: Cell. 2011 Nov 11;147(4):948.

21.

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA.

Nature. 2011 Jul 6;475(7354):106-9. doi: 10.1038/nature10189.

22.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.

Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

23.

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

Karreth FA, DeNicola GM, Winter SP, Tuveson DA.

Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017.

24.

Modelling oncogenic Ras/Raf signalling in the mouse.

Karreth FA, Tuveson DA.

Curr Opin Genet Dev. 2009 Feb;19(1):4-11. doi: 10.1016/j.gde.2008.12.006. Epub 2009 Feb 7. Review.

Supplemental Content

Loading ...
Support Center